Table I.
Expression of IL-32 in human tumour tissues.
| Tumour | Methods | IL-32 expression and prognosis | (Refs.) |
|---|---|---|---|
| Hepatocellular carcinoma | DNA microarray chips, RT-PCR, IHC, WB | Higher in tumour tissues than in normal tissues | (9) |
| Pancreatic cancer | RT-PCR, IHC | Higher in tumour tissues than in pancreatic or normal tissues | (10) |
| Oesophageal cancer | RT-PCR, IHC WB, ELISA | Higher in tumour tissues and patients' serum than in normal subjects | (11) |
| Lung cancer | RT-PCR, IHC LCM | High in tumour tissues with a histology-specific association; correlation with worse prognosis revealed | (40) |
| Gastric cancer | RT-PCR, IHC | Higher in gastric carcinomas than in corresponding normal mucosa; correlates with tumour progression and poor prognosis | (13) |
| Breast cancer | RT-PCR, IHC | Higher in tumour tissues than in normal tissues; correlates with tumour size, number of lymph node metastases and tumour stage | (15) |
| Cutaneous T-cell lymphoma | RT-PCR, IHC | Higher in tumour tissues than in normal tissues; correlated with CCL17 and CCL18 expression | (16) |
| ELISA | Correlated with disease activity |
RT-qPCR, reverse transcription-quantitative polymerase chain reaction; IHC, immunohistochemistry; WB, western blot analysis; LCM, laser capture microdissection.